17,261 trials
Invasive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Change in Ki-67 Expression Assessed in Tumor Tissue by Immunohistochemistry — 1.3 percentage of cells expressing Ki67
HLRCC · Sporadic Papillary Renal Cell Cancer
Primary: Overall Response Rate — 72; 35 Percentage of participants
Rheumatoid Arthritis · Psoriatic Arthritis · Ankylosing Spondylitis
Primary: Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13 — 13.0; 7.5 percentage of participants
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
KRAS Gene Mutation · Metastatic Malignant Neoplasm in the Brain · Recurrent Non-Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 3.7 months
Alcoholic Hepatitis
Primary: Survival at 90 Days — 90; 70 percentage of participants
Glabellar Lines
Primary: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7…
Donor Site Complication
Primary: Number of Participants With Treatment-related AEs and SAEs (Including Infections and Bleeding) — 0; 0; 0; 0 Participants
Asthma
Primary: Maximum Observed Mometasone Furoate Plasma Concentration (Cmax) — 51.9; 53.5 pg/mL
Hepatocellular Carcinoma (HCC)
Primary: Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC) — 12.9 Percentage of participants — p=0.0001
Adult Myelodysplastic Syndrome · Anemia · Chronic Myelomonocytic Leukemia
Primary: Number of Patients Demonstrating Overall Hematologic Improvement (HI) — 6; 5; 7 Participants
Hidradenitis Suppurativa · Acne Inversa · Suppurative Hidradenitis
Primary: Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 46.2; 44.0; 54.9 Percentage of participants
Mitochondrial Function · Physical Function
Primary: Change From Baseline in Mitochondrial Respiration in Muscle — -3.05; -4.82; -4.56 nmol O2/s/mg wwt
Peanut Allergy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 5; 0; 0 Participants
Opioid-use Disorder · Opioid Dependence · Opiate Dependence
Primary: Mean Urinary Buprenorphine Levels — 861; 287 ng/ml — p=.1